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Abstract 
Purpose: To investigate the effect of epigallocatechin-3-gallate (EGCG) on bone metabolism and 
osteoblastic activity. 
Methods: MG-63 human osteoblast-like cells were treated with varied concentrations of EGCG. 
Alkaline phosphatase (ALP) activity and matrix mineralization assays were carried out on the treated 
and untreated MG-63 human osteoblast-like cells. Beta-catenin mRNA level was determined by 
quantitative real-time polymerase chain reaction (q-PCR).  
Results: The results showed that EGCG treatment significantly increased ALP and mineralization 
activities at concentrations of 15 and 30 μM, in a dose-dependent manner. Furthermore, EGCG 
treatment significantly increased beta-catenin mRNA expression by 70.7 ± 11.0 and 126.7 ± 35.1 %, 
respectively, at EGCG concentration of 15 and 30 μM. In addition, the stimulating effect of EGCG 
treatment on ALP activity was abolished by co-treatment with ICI 182,780, an antagonist of estrogen 
receptor (ER). Again, the increase in beta-catenin MRNA, when treated with EGCG, was inhibited by 
co-treatment with ICI 182,780.  
Conclusion: EGCG promotes osteoblastic activity in human osteoblast-like cells, by Wnt signaling 
through estrogen receptor (ER) pathway. 
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Osteoporosis is a musculoskeletal disease 
characterized by low bone mineral density (BMD) 
and high risk of fragility fractures. Osteoporosis 
has drawn more and more attention from medical 
researchers because it is becoming an 
increasing risk for human health and quality of 
life [1].  Osteoporosis is caused by imbalance 
between bone formation and bone resorption, 
which relies on the interactions between 
osteoblasts and osteoclasts [2,3]. Osteoblasts, 
known as bone-forming cells, are the major 
osteoprogenitor cells, whose proliferation and 
differentiation will eventually result in the 
formation of the mineralized extracellular matrix 
[4]. 
 
To date, one effective solution to treat 
osteoporosis is targeted on osteoblasts by 
increasing the proliferation of the osteoblastic 
lineage and promoting the differentiation of 
osteoblasts, and eventually to induce new bone 
formation [5]. The functions of osteoblasts can be 
regulated by various local and hormonal factors 
such as Wnt glycoproteins. Canonical Wnt/beta-
catenin signaling pathway plays an important role 
in the maintenance of bone mass and bone 
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formation [6]. Wnt ligands binding to the frizzled 
receptor will lead to accumulation and 
stabilization of beta-catenin in the cytoplasm [7]. 
Recent studies demonstrate that beta-catenin 
through Wnt signaling is essential in skeletal 
development through the regulation of 
osteoblastogenesis [7,8]. 
 
Epigallocatechin-3-gallate (EGCG), a component 
of green tea, has been demonstrated to possess 
various biological activities, including anti-cancer, 
anti-inflammation, anti-bacteria and so on [9-11]. 
In the present study, we studied the effects of 
EGCG on bone metabolism regarding 
osteoblastic activity in MG-63 human osteoblast-





Cell culture and cell viability assay 
 
Human osteoblast-like MG-63 cells were 
obtained from the Institute of Biochemistry and 
Cell Biology, the Chinese Academy of Science, 
Shanghai, China. The cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM; 
Life Technologies, CA, USA), containing 10 % 
fetal bovine serum (FBS; Life Technologies, CA, 
USA) and 1 % penicillin and streptomycin (PS; 
Life Technologies, CA, USA) in a humidified 
incubator at 37 °C with 5 % CO2. Cell viability 
was determined by the 3-[4, 5-dimethylthiazol-2-
yl]-2, 5-diphenyltetrazolium bromide (MTT; 
Sigma, St. Louis, MO). MG-63 cells were plated 
in 96-well plates (5 × 103 cells/well) and treated 
with various concentrations of EGCG (7.5 – 30 
μM) for three days. MTT solution at a 
concentration of 5 mg/mL was added into each 
well and incubated for another 2 h. The optical 
density [12] at 540 nm was measured and 
expressed as the percentage of vehicle control. 
 
Alkaline phosphatase (ALP) activity assay 
 
ALP activity was determined using a commercial 
Alkaline Phosphatase Microwell Substrate 
System (Sigma, St. Louis, MO) following the 
manufacturer’s instruction. After treatment with 
various concentrations of EGCG (7.5 – 30 μM) 
for 4 days, the cell monolayer was gently rinsed 
twice with ice cold PBS and lysed with lysis 
buffer containing 0.1 % Triton X-100, 50mM Tris-
HCl (pH 7.2), and 2 mM MgCl2. The supernatant 
was collected after the lysate was centrifuged at 
14,000 xg for 10 min at 4 °C. ALP activity in the 
clear supernatant was measured with ALP 
activity assay kit and the total protein 
concentration was determined with a BCA-
protein assay kit. 
 
Matrix mineralization assay 
 
The degree of matrix mineralization of MG-63 
cells was determined by Alizarin Red S staining 
method after EGCG treatment for 6 days [13]. 
Cells were washed twice with cold PBS and fixed 
with cold 70 % ethanol (v/v) for 30 min. Next, the 
cells were rinsed with distilled water and exposed 
to 40 mM Alizarin Red S solution (pH 4.2) for 10 
min. After removing the unbonded stain by 
rinsing three times with distilled water, the 
amount of stain on the tested cells was extracted 
by shaking the cells with 10 mM sodium 
phosphate containing 10 % cetylpyridinium 
chloride (Sigma, USA) for 15 min. The values 
were then determined at an optical density of 562 
nm. The data were expressed as percentage 
relative to the vehicle control group, after the 
relative matrix mineralization values were 
normalized by the relative cell viability. 
 
RNA extraction and quantitative real-time 
polymerase chain reaction (q-PCR) 
 
The expression of beta-catenin mRNA was 
evaluated by q-PCR. The total RNA was 
extracted with TRIzol® reagent (Life 
Technologies, NY, USA), according to the 
manufacturer’s instructions. In the experiment, 1 
μg RNA was used for the reverse transcription 
reaction using Oligo dT (18T) (Omega, NY, 
USA). Nucleotide sequences of primer for beta-
catenin were: forward, 5’-gccacaggattacaagaagc-
3’; reverse, 5’-ccaccagagtgaaaagaacg-3’.  
 
In our experiment, PCR was carried out in 
duplicate with SYBR Green PCR Master Mix 
using a 7900HT qPCR system thermal cycler 
(Applied Biosystems, CA). Beta-actin mRNA was 
used as internal control for each sample. The Ct 
values for each sample were normalized to beta-
actin mRNA. Nucleotide sequences of primers 
for beta-actin were: forward, 5’-ttctacaatga 
gctgcgtgtg-3’, reverse, 5’-ggggtgttgaaggtctcaaa-





The data were shown as the mean ± standard 
deviation from three independent tests. One-way 
analysis of variance (ANOVA) followed by 
Dunnett test was performed using Graph Pad 
Prism software version 5.0 for statistical analysis. 
In all experiments, p < 0.05 was considered 
statistically significant. 
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Effects of EGCG on cell viability of MG-63 
human osteoblast-like cells  
 
After treatment with various concentrations (7.5 – 
30 μM) of EGCG for 3 days, cell viability was 
determined by the MTT assay. The data showed 
that EGCG did not affect the cell viability of MG-
63 cells at the tested concentrations (Fig 1), 
indicating that EGCG was not cytotoxic to MG-63 




Fig 1: Effect of EGCG on cell viability of MG-63 
human osteoblast-like cells. Values are expressed as 
mean ± standard deviation (n = 3); p > 0.05, compared 
with vehicle control 
 
Effects of EGCG on ALP activity of MG-63 
human osteoblast-like cells 
 
In order to determine whether EGCG could 
increase osteoblastic cell differentiation, its effect 
on ALP activity as investigated. Our results 
showed that treatment of MG-63 cells with 
EGCG for 4 days dose-dependently stimulated 
ALP activity in the cells. ALP activity was 
remarkably increased by 37.1 ± 10.6 and 75.6 ± 
9.5 % with EGCG treatment at 15 and 30 μM, 
respectively, when compared with the vehicle 




Fig 2: Effects of EGCG on ALP activity of MG-63 
human osteoblast-like cells. Values are expressed as 
mean ± standard deviation; ** p < 0.01, *** p < 0.001 
versus control group 
Effect of EGCG on mineralization activity of 
MG-63 human osteoblast-like cells 
 
The matrix mineralization assay was also 
evaluated for further studying the effects of 
EGCG on osteoblastic activity. The data 
demonstrated that EGCG treatment also 
significantly promoted the matrix mineralization 
at 15 and 30 μM, by 47.3 ± 9.1 and 82.7 ± 15.2 




Fig 3: Effects of EGCG on mineralization activity of 
MG-63 human osteoblast-like cells. Values are 
expressed as mean ± standard deviation; *** p < 0.001 
versus control group 
 
Effect of EGCG on beta-catenin mRNA 
expression in MG-63 human osteoblast-like 
cells  
 
Beta-catenin is an important molecule for Wnt 
signaling pathway, which plays a crucial role in 
bone formation. Therefore, to determine whether 
Wnt signaling pathway was involved in the 
effects of EGCG on osteoblastic activity, beta-
catenin mRNA expression levels in MG-63 cells 
were evaluated after EGCG treatment. As shown 
in Fig 4, EGCG treatment significantly increased 
the beta-catenin mRNA expression. The beta-
catenin mRNA levels were increased by 70.7 ± 
11.0 and 126.7 ± 35.1 %, respectively by EGCG 
treatment at 15 and 30 μM. 
 
 
Fig 4: Effect of EGCG on beta-catenin mRNA 
expression in MG-63 human osteoblast-like cells. 
Values are expressed as mean ± standard deviation; 
** p < 0.01, *** p < 0.001 versus control group 
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Effects of EGCG on osteoblastic activities in 
MG-63 human osteoblast-like cells after co-
treatment with ICI182780 
 
To determine whether estrogen receptor (ER) 
was involved in EGCG activated osteoblastic 
activities, ICI 182,780, an antagonist of ER was 
co-treated with EGCG on MG-63 cells. Our data 
showed that the stimulative effects of EGCG 
treatment on ALP activity were abolished by ICI 
182,780 (1 μg/ml) co-treatment. In addition, the 
increasing mRNA level of beta-catenin by EGCG 
treatment was also inhibited by ICI 182,780 co-
treatment (Fig 5). 
 
 
Fig 5: Effects of EGCG on osteoblastic activities of 
MG-63 human osteoblast-like cells after co-treatment 
with ICI182780 (1 μg/ml). Values are expressed as 
mean ± standard deviation; ** p < 0.01, *** p < 0.001 




In the present study, EGCG was found to be 
capable of increasing ALP activity and 
mineralization activity, in a dose-dependent 
manner. Besides, EGCG treatment significantly 
increased after beta-catenin mRNA expression 
by 70.7 ± 11.0 and 126.7 ± 35.1 %, respectively 
by EGCG treatment at 15 and 30 μM. 
Furthermore, the stimulating effects of EGCG 
treatment on ALP activity were abolished by co-
treatment with ICI 182,780, an antagonist of 
estrogen receptor (ER). In addition, the 
increasing mRNA level of beta-catenin by EGCG 
treatment was also inhibited by ICI 182,780 co-
treatment. 
 
Osteoblasts play an important role in the process 
of osteoporosis. Among various osteoblast 
differentiation markers, ALP is known as a 
representative marker for the early stage of 
differentiation, and is a critical indicator of the 
initiation of mineralization during bone formation 
[2]. In our results, EGCG could significantly 
increase ALP activity and also the mineralization 
activity, indicating that EGCG has great potential 
in promoting osteoblastic activities.  
 
Wnt/beta-catenin pathway plays an essential role 
in bone mass accrual, regulation and 
maintenance [12]. Scientific evidence reveals 
that beta-catenin is an important mediator in the 
Wnt signaling pathway, which plays a crucial role 
in bone formation [14]. Researchers also find that 
deletion of the beta-catenin gene will inhibit the 
proliferation and differentiation of osteoblasts 
[15]. In the current study, EGCG significantly 
increased the beta-catenin mRNA in MG-63 
cells, indicating that the Wnt/beta-catenin 
pathway is involved in the actions of EGCG in 
osteoblasts. ER also plays a significant role the 
proliferation and differentiation of osteoblasts, 
and subsequently bone remodeling and 
development of the skeleton [16].  
 
Clinical data show that human ER genes are 
positively related with femoral fracture and bone 
metabolism [17]. In our study, blocking ER with 
the antagonist ICI 182,780 also inhibited the 
beneficial effects of EGCG in MG-63, suggesting 





Taken together, the findings demonstrate that 
EGCG promotes osteoblastic activity in human 
osteoblast-like cells, which may involve Wnt 
signaling through ER pathway. All the findings 
strongly suggest that EGCG needs to be further 
studied with a view to developing an effective 




1. Willson T, Nelson SD, Newbold J, Nelson RE, LaFleur J. 
The clinical epidemiology of male osteoporosis: A 
review of the recent literature. Clin Epidemiol 2015; 7: 
65-76. 
2. Zhang C, Peng J, Wu S, Jin Y, Xia F, Wang C, Liu K, Sun 
H, Liu M. Dioscin promotes osteoblastic proliferation and 
differentiation via lrp5 and er pathway in mouse and 
human osteoblast-like cell lines. J Biomed Sci 2014; 21: 
30-42. 
3. Lee YS, Choi EM. Costunolide stimulates the function of 
osteoblastic mc3t3-e1 cells. Int Immunopharmacol 2011; 
11: 712-718. 
4. Ducy P, Schinke T, Karsenty G. The osteoblast: A 
sophisticated fibroblast under central surveillance. 
Science 2000; 289: 1501-1504. 
5. Lane NE, Kelman A. A review of anabolic therapies for 
osteoporosis. Arthritis Res Ther 2003; 5: 214-222. 
Peng et al 
Trop J Pharm Res, February 2016; 15(2): 317  
 
6. Zhou J, He H, Yang L, Chen S, Guo H, Xia L, Liu H, Qin 
Y, Liu C, Wei X, Zhou Y. Effects of pulsed 
electromagnetic fields on bone mass and wnt/beta-
catenin signaling pathway in ovariectomized rats. Arch 
Med Res 2012: 43: 274-282. 
7. Wang Y, Li YP, Paulson C, Shao JZ, Zhang X, Wu M, 
Chen W. Wnt and the wnt signaling pathway in bone 
development and disease. Front Biosci (Landmark Ed) 
2014; 19: 379-407. 
8. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann 
C. Canonical wnt/beta-catenin signaling prevents 
osteoblasts from differentiating into chondrocytes. Dev 
Cell 2005; 8: 727-738. 
9. Yang CS, Li G, Yang Z, Guan F, Chen A, Ju J. Cancer 
prevention by tocopherols and tea polyphenols. Cancer 
Lett 2013; 334: 79-85. 
10. Singh R, Akhtar N, Haqqi TM. Green tea polyphenol 
epigallocatechin-3-gallate: Inflammation and arthritis. 
[corrected]. Life Sci 2010; 86: 907-918. 
11. Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-
infective properties of epigallocatechin-3-gallate (egcg), 
a component of green tea. Br J Pharmacol 2013; 168: 
1059-1073. 
12. Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, Cullen 
DM, Zhao W, Li C, Kharode Y, Sauter L, Babij P, Brown 
EL, Hill AA. Wnt/beta-catenin signaling is a normal 
physiological response to mechanical loading in bone. J 
Biol Chem 2006; 281: 31720-31728. 
13. Ko CH, Lau KM, Choy WY, Leung PC. Effects of tea 
catechins, epigallocatechin, gallocatechin, and 
gallocatechin gallate, on bone metabolism. J Agric Food 
Chem 2009; 57: 7293-7297. 
14. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber 
PB, Feng JQ, Bonewald LF, Kneissel M. Osteocyte 
wnt/beta-catenin signaling is required for normal bone 
homeostasis. Mol Cell Biol 2010; 30: 3071-3085. 
15. Golovchenko S, Hattori T, Hartmann C, Gebhardt M, 
Gebhard S, Hess A, Pausch F, Schlund B, von der Mark 
K. Deletion of beta catenin in hypertrophic growth plate 
chondrocytes impairs trabecular bone formation. Bone 
2013; 55: 102-112. 
16. Borjesson AE, Lagerquist MK, Windahl SH, Ohlsson C. 
The role of estrogen receptor alpha in the regulation of 
bone and growth plate cartilage. Cell Mol Life Sci 2013; 
70: 4023-4037. 
17. Honma N, Mori S, Zhou H, Ikeda S, Mieno MN, Tanaka 
N, Takubo K, Arai T, Sawabe M, Muramatsu M, Ito H. 
Association between estrogen receptor-beta 
dinucleotide repeat polymorphism and incidence of 
femoral fracture. J Bone Miner Metab 2013; 31: 96-101. 
  
